Enhanced Cytotoxicity to Lung Cancer Cells by Mitochondrial Delivery of Camptothecin.

[1]  Shufeng Chen,et al.  Development of ligand modified erythrocyte coated polydopamine nanomedicine to codeliver chemotherapeutic agent and oxygen for chemo-photothermal synergistic cancer therapy. , 2022, International journal of pharmaceutics.

[2]  A. Pawar,et al.  Delocalized Lipophilic Cation Triphenyl phosphonium: Promising Molecule for Mitochondria Targeting. , 2022, Current drug delivery.

[3]  V. Bacherikov.  Total Synthesis, Mechanism of Action and Antitumor Efficacy of Camptothecin and Some of Its Analogues. , 2022, Anti-cancer agents in medicinal chemistry.

[4]  J. Das,et al.  In vivo therapeutic evaluation of a novel bis-lawsone derivative against tumor following delivery using mesoporous silica nanoparticle based redox-responsive drug delivery system. , 2021, Materials science & engineering. C, Materials for biological applications.

[5]  Linghao Qin,et al.  pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer , 2021, Journal of Nanobiotechnology.

[6]  I. Mohammad,et al.  Self-assembled nanomedicine combining a berberine derivative and doxorubicin for enhanced antitumor and antimetastatic efficacy via mitochondrial pathways. , 2021, Nanoscale.

[7]  C. Soto-Sánchez,et al.  Development of a Prodrug of Camptothecin for Enhanced Treatment of Glioblastoma Multiforme , 2021, Molecular pharmaceutics.

[8]  C. Cai,et al.  Decreased ferroportin in hepatocytes promotes macrophages polarize towards an M2-like phenotype and liver fibrosis , 2021, Scientific Reports.

[9]  Linghao Qin,et al.  Folic Acid-Modified Erythrocyte Membrane Loading Dual Drug for Targeted and Chemo-Photothermal Synergistic Cancer Therapy. , 2020, Molecular pharmaceutics.

[10]  Yumei Xiao,et al.  TPP-based mitocans: a potent strategy for anticancer drug design. , 2020, RSC medicinal chemistry.

[11]  J. Ji,et al.  ATP Suppression by pH-Activated Mitochondria-Targeted Delivery of Nitric Oxide Nanoplatform for Drug Resistance Reversal and Metastasis Inhibition. , 2020, Small.

[12]  Linghao Qin,et al.  Folic acid modified nanoerythrocyte for codelivery of paclitaxel and tariquidar to overcome breast cancer multidrug resistance. , 2020, Molecular pharmaceutics.

[13]  Jian-hai Chen,et al.  Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis , 2020, Journal of Nanobiotechnology.

[14]  W. Wierda,et al.  Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies , 2019, Drugs.

[15]  Linghao Qin,et al.  Surface-Modified Nanoerythrocyte Loading DOX for Targeted Liver Cancer Chemotherapy. , 2018, Molecular pharmaceutics.

[16]  Fengzhi Li,et al.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? , 2017, American journal of cancer research.

[17]  Yongmei Li,et al.  3‐O‐(Z)‐coumaroyloleanolic acid overcomes Cks1b‐induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways , 2017, Biochemical pharmacology.

[18]  Min Huang,et al.  Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation , 2017, Cell Research.

[19]  P. Botella,et al.  Safe approaches for camptothecin delivery: Structural analogues and nanomedicines , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[20]  A. Concheiro,et al.  Polymeric prodrug-functionalized polypropylene films for sustained release of salicylic acid. , 2016, International journal of pharmaceutics.

[21]  Sudipta Basu,et al.  Nanoparticle-Mediated Mitochondrial Damage Induces Apoptosis in Cancer. , 2016, ACS applied materials & interfaces.

[22]  Yanli Zhao,et al.  Targeted delivery of doxorubicin to mitochondria using mesoporous silica nanoparticle nanocarriers. , 2015, Nanoscale.

[23]  Yung-Hyun Choi,et al.  Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs. , 2014, Environmental toxicology and pharmacology.

[24]  S. Dhar,et al.  Detouring of cisplatin to access mitochondrial genome for overcoming resistance , 2014, Proceedings of the National Academy of Sciences.

[25]  S. Mitragotri,et al.  Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles. , 2013, ACS nano.

[26]  S. Mani,et al.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. , 2013, Current drug targets.

[27]  Chi Woo Yoon,et al.  Reactive oxygen species responsive nanoprodrug to treat intracranial glioblastoma. , 2013, ACS nano.

[28]  A. Desideri,et al.  A natural anticancer agent thaspine targets human topoisomerase IB. , 2013, Anti-cancer agents in medicinal chemistry.

[29]  M. Minden,et al.  Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. , 2011, Chemistry & biology.

[30]  E. Rosen,et al.  Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms , 2009, Anti-cancer drugs.

[31]  Leroy F. Liu,et al.  Mechanism of Action of Camptothecin , 1996, Annals of the New York Academy of Sciences.